Allakos Inc
NASDAQ:ALLK
Intrinsic Value
Allakos, Inc. engages in the development of therapeutic antibodies. [ Read More ]
The intrinsic value of one ALLK stock under the Base Case scenario is 1.94 USD. Compared to the current market price of 1.05 USD, Allakos Inc is Undervalued by 46%.
Valuation Backtest
Allakos Inc
Run backtest to discover the historical profit from buying and selling ALLK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Allakos Inc
Current Assets | 179.9m |
Cash & Short-Term Investments | 170.8m |
Other Current Assets | 9.1m |
Non-Current Assets | 63.7m |
PP&E | 57.5m |
Other Non-Current Assets | 6.2m |
Current Liabilities | 36.6m |
Accounts Payable | 1.8m |
Accrued Liabilities | 34.2m |
Other Current Liabilities | 628k |
Non-Current Liabilities | 38.2m |
Other Non-Current Liabilities | 38.2m |
Earnings Waterfall
Allakos Inc
Revenue
|
0
USD
|
Operating Expenses
|
-196.1m
USD
|
Operating Income
|
-196.1m
USD
|
Other Expenses
|
10.4m
USD
|
Net Income
|
-185.7m
USD
|
Free Cash Flow Analysis
Allakos Inc
ALLK Profitability Score
Profitability Due Diligence
Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ALLK Solvency Score
Solvency Due Diligence
Allakos Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Allakos Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALLK Price Targets Summary
Allakos Inc
According to Wall Street analysts, the average 1-year price target for ALLK is 2.96 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.
Ownership
ALLK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALLK Price
Allakos Inc
Average Annual Return | 19.94% |
Standard Deviation of Annual Returns | 100.12% |
Max Drawdown | -99% |
Market Capitalization | 92.1m USD |
Shares Outstanding | 87 874 000 |
Percentage of Shares Shorted | 8.29% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Contact
IPO
Employees
Officers
The intrinsic value of one ALLK stock under the Base Case scenario is 1.94 USD.
Compared to the current market price of 1.05 USD, Allakos Inc is Undervalued by 46%.